Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, Pete Yeung V, Rennerfeldt DA, Henkensiefken A, Fox M, Lam S, Morrissey KM, Lange Z, Podust VN, Derynck MK, Irving BA, Schellenberger V.
Cattaruzza F, et al. Among authors: rennerfeldt da.
Nat Cancer. 2023 Apr;4(4):485-501. doi: 10.1038/s43018-023-00536-9. Epub 2023 Mar 30.
Nat Cancer. 2023.
PMID: 36997747
Free PMC article.